Q1 Earnings Forecast for INKT Issued By William Blair

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a report issued on Tuesday, March 18th. William Blair analyst M. Phipps expects that the company will earn ($0.71) per share for the quarter. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. William Blair also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.71) EPS and Q4 2026 earnings at ($0.68) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a research report on Tuesday.

MiNK Therapeutics Trading Up 8.2 %

Shares of INKT stock opened at $9.10 on Thursday. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $19.00. The stock has a market capitalization of $36.09 million, a P/E ratio of -2.33 and a beta of 0.16. The firm’s 50 day moving average is $8.96 and its 200 day moving average is $7.76.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12).

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.